
    
      OUTLINE:

      Patients receive decitabine intravenously (IV) once daily (QD) over 1 hour on days 1-10, and
      either ruxolitinib orally (PO) twice daily (BID) or fedratinib PO daily on days 1-28.
      Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for up to 5 years.
    
  